{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Chirinos J"],"funding":["NCATS NIH HHS"],"pubmed_abstract":["Background Abnormal cellular lipid metabolism appears to underlie SARS-CoV-2 cytotoxicity and may involve inhibition of peroxisome proliferator activated receptor alpha (PPARα). Fenofibrate, a PPAR-α activator, modulates cellular lipid metabolism. Fenofibric acid has also been shown to affect the dimerization of angiotensin-converting enzyme 2, the cellular receptor for SARS-CoV-2. Fenofibrate and fenofibric acid have been shown to inhibit SARS-CoV-2 replication in cell culture systems <i>in vitro</i> . Methods We randomly assigned 701 participants with COVID-19 within 14 days of symptom onset to 145 mg of fenofibrate (nanocrystal formulation with dose adjustment for renal function or dose-equivalent preparations of micronized fenofibrate or fenofibric acid) vs. placebo for 10 days, in a d"],"journal":["Research square"],"pagination":["rs.3.rs-1933913"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9387540"],"repository":["biostudies-literature"],"pubmed_title":["A Randomized Trial of Lipid Metabolism Modulation with Fenofibrate for Acute Coronavirus Disease 2019."],"pmcid":["PMC9387540"],"funding_grant_id":["U01 TR003734"],"pubmed_authors":["Giamarellos-Bourboulis E","Gomez-Laiton E","Sanchez G","Greczylo C","Hernandez JR","Villavicencio-Carranza M","Danos WL","Perez-Mayorga M","Milionis H","Katsaounou P","Castro-Callirgos C","Greene K","Saldarriaga MC","Chittams J","Cure-Cure C","Sharkoski T","Giraldo MC","Rosado-Santander N","Moghnieh R","Pereyra R","Poulakou G","Ayala-Garcia R","Arbanil H","Rodriguez-Mori J","Dimitroulis I","Gutierrez C","Pourmussa B","Accini-Mendoza J","Valdivia-Vega R","Sympardi S","Pariona M","Vlachopoulos C","Sweitzer N","Gonzalez-Hernandez L","Chirinos J","Putt M","Lopez-Jaramillo P","Angeliki R","Davila-Del-Carpio G","Cohen J","Salman O","Medina C","Carrasco RA","Alexiou Z","Bizri A","Andrade-Villanueva J"],"additional_accession":[]},"is_claimable":false,"name":"A Randomized Trial of Lipid Metabolism Modulation with Fenofibrate for Acute Coronavirus Disease 2019.","description":"Background Abnormal cellular lipid metabolism appears to underlie SARS-CoV-2 cytotoxicity and may involve inhibition of peroxisome proliferator activated receptor alpha (PPARα). Fenofibrate, a PPAR-α activator, modulates cellular lipid metabolism. Fenofibric acid has also been shown to affect the dimerization of angiotensin-converting enzyme 2, the cellular receptor for SARS-CoV-2. Fenofibrate and fenofibric acid have been shown to inhibit SARS-CoV-2 replication in cell culture systems <i>in vitro</i> . Methods We randomly assigned 701 participants with COVID-19 within 14 days of symptom onset to 145 mg of fenofibrate (nanocrystal formulation with dose adjustment for renal function or dose-equivalent preparations of micronized fenofibrate or fenofibric acid) vs. placebo for 10 days, in a d","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-04-08T11:10:47.407Z","creation":"2025-04-19T22:46:06.349Z"},"accession":"S-EPMC9387540","cross_references":{"pubmed":["35982675"],"doi":["10.21203/rs.3.rs-1933913/v1"]}}